VTRS
Viatris Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$18.37B
5Y Perf.-6.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
VTRS vs TEVA
Revenue, margins, valuation, and 5-year total return — side by side.
TEVA
Teva Pharmaceutical Industries Limited
Drug Manufacturers - Specialty & Generic
Market Cap$42.31B
5Y Perf.+190.0%
VTRS vs TEVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VTRS | TEVA |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $18.37B | $42.31B |
| Revenue (TTM) | $14.30B | $17.35B |
| Net Income (TTM) | $-3.51B | $1.56B |
| Gross Margin | 35.1% | 52.1% |
| Operating Margin | -18.6% | 13.2% |
| Forward P/E | 6.5x | 14.7x |
| Total Debt | $14.41B | $17.38B |
| Cash & Equiv. | $1.32B | $3.56B |
VTRS vs TEVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VTRS
TEVA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Viatris Inc. (VTRS) | 100 | 93.4 | -6.6% |
| Teva Pharmaceutical… (TEVA) | 100 | 290.0 | +190.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VTRS vs TEVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TEVA leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Viatris Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
VTRS
Viatris Inc.
The Income Pick
VTRS is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 0.99, yield 3.0%
- Lower volatility, beta 0.99, Low D/E 98.0%, current ratio 5.06x
- Beta 0.99, yield 3.0%, current ratio 5.06x
Best for: income & stability and sleep-well-at-night
TEVA
Teva Pharmaceutical Industries Limited
The Growth Play
TEVA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 4.3%, EPS growth 182.8%, 3Y rev CAGR 5.0%
- -24.0% 10Y total return vs VTRS's -53.8%
- 4.3% revenue growth vs VTRS's -3.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TEVA | 4.3% revenue growth vs VTRS's -3.0% |
| Value | VTRS | Lower P/E (6.5x vs 14.7x) |
| Quality / Margins | TEVA | 9.0% margin vs VTRS's -24.6% |
| Stability / Safety | VTRS | Beta 0.99 vs TEVA's 1.13, lower leverage |
| Dividends | VTRS | 3.0% yield; the other pay no meaningful dividend |
| Momentum (1Y) | TEVA | +125.4% vs VTRS's +93.8% |
| Efficiency (ROA) | TEVA | 3.9% ROA vs VTRS's -9.5%, ROIC 7.7% vs -6.7% |
VTRS vs TEVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
VTRS vs TEVA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTEVALAGGINGVTRS
VTRSViatris Inc.
1leads
TEVATeva Pharmaceutical I…
4leads
6 Total Categories
CATEGORYLEADERvs VTRSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TEVA4/6
Valuation MetricsMultiples, price ratios, and targets
VTRS5/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TEVA6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TEVA5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
TEVA1/1
Income & Cash Flow (Last 12 Months)
TEVA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TEVA and VTRS operate at a comparable scale, with $17.3B and $14.3B in trailing revenue. TEVA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to VTRS's -24.6%.
| Metric | VTRSViatris Inc. | TEVATeva Pharmaceutic… |
|---|---|---|
| RevenueTrailing 12 months | $14.3B | $17.3B |
| EBITDAEarnings before interest/tax | -$559M | $3.3B |
| Net IncomeAfter-tax profit | -$3.5B | $1.6B |
| Free Cash FlowCash after capex | $1.8B | $1.2B |
| Gross MarginGross profit ÷ Revenue | +35.1% | +52.1% |
| Operating MarginEBIT ÷ Revenue | -18.6% | +13.2% |
| Net MarginNet income ÷ Revenue | -24.6% | +9.0% |
| FCF MarginFCF ÷ Revenue | +12.7% | +6.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.0% | +2.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +30.2% | +72.2% |
TEVA leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
VTRS leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
| Metric | VTRSViatris Inc. | TEVATeva Pharmaceutic… |
|---|---|---|
| Market CapShares × price | $18.4B | $42.3B |
| Enterprise ValueMkt cap + debt − cash | $31.5B | $56.1B |
| Trailing P/EPrice ÷ TTM EPS | -5.32x | 30.28x |
| Forward P/EPrice ÷ next-FY EPS est. | 6.53x | 14.68x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 17.77x |
| Price / SalesMarket cap ÷ Revenue | 1.28x | 2.45x |
| Price / BookPrice ÷ Book value/share | 1.27x | 5.39x |
| Price / FCFMarket cap ÷ FCF | 9.48x | 36.85x |
VTRS leads this category, winning 5 of 5 comparable metrics.
Profitability & Efficiency
TEVA leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
TEVA delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-24 for VTRS. VTRS carries lower financial leverage with a 0.98x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x. On the Piotroski fundamental quality scale (0–9), TEVA scores 8/9 vs VTRS's 5/9, reflecting strong financial health.
| Metric | VTRSViatris Inc. | TEVATeva Pharmaceutic… |
|---|---|---|
| ROE (TTM)Return on equity | -23.9% | +20.7% |
| ROA (TTM)Return on assets | -9.5% | +3.9% |
| ROICReturn on invested capital | -6.7% | +7.7% |
| ROCEReturn on capital employed | -7.5% | +8.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 8 |
| Debt / EquityFinancial leverage | 0.98x | 2.20x |
| Net DebtTotal debt minus cash | $13.1B | $13.8B |
| Cash & Equiv.Liquid assets | $1.3B | $3.6B |
| Total DebtShort + long-term debt | $14.4B | $17.4B |
| Interest CoverageEBIT ÷ Interest expense | -6.30x | 2.51x |
TEVA leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TEVA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TEVA five years ago would be worth $35,311 today (with dividends reinvested), compared to $13,151 for VTRS. Over the past 12 months, TEVA leads with a +125.4% total return vs VTRS's +93.8%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.9% vs VTRS's 21.0% — a key indicator of consistent wealth creation.
| Metric | VTRSViatris Inc. | TEVATeva Pharmaceutic… |
|---|---|---|
| YTD ReturnYear-to-date | +29.0% | +17.4% |
| 1-Year ReturnPast 12 months | +93.8% | +125.4% |
| 3-Year ReturnCumulative with dividends | +77.1% | +301.0% |
| 5-Year ReturnCumulative with dividends | +31.5% | +253.1% |
| 10-Year ReturnCumulative with dividends | -53.8% | -24.0% |
| CAGR (3Y)Annualised 3-year return | +21.0% | +58.9% |
TEVA leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — VTRS and TEVA each lead in 1 of 2 comparable metrics.
Risk & Volatility
VTRS is the less volatile stock with a 0.99 beta — it tends to amplify market swings less than TEVA's 1.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | VTRSViatris Inc. | TEVATeva Pharmaceutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.99x | 1.13x |
| 52-Week HighHighest price in past year | $16.47 | $37.35 |
| 52-Week LowLowest price in past year | $8.19 | $14.99 |
| % of 52W HighCurrent price vs 52-week peak | +96.8% | +97.3% |
| RSI (14)Momentum oscillator 0–100 | 71.3 | 71.9 |
| Avg Volume (50D)Average daily shares traded | 10.1M | 6.5M |
Evenly matched — VTRS and TEVA each lead in 1 of 2 comparable metrics.
Analyst Outlook
TEVA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates VTRS as "Hold" and TEVA as "Buy". Consensus price targets imply 7.3% upside for TEVA (target: $39) vs -4.4% for VTRS (target: $15). VTRS is the only dividend payer here at 3.01% yield — a key consideration for income-focused portfolios.
| Metric | VTRSViatris Inc. | TEVATeva Pharmaceutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $15.25 | $39.00 |
| # AnalystsCovering analysts | 12 | 46 |
| Dividend YieldAnnual dividend ÷ price | +3.0% | — |
| Dividend StreakConsecutive years of raises | 0 | 1 |
| Dividend / ShareAnnual DPS | $0.48 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.7% | 0.0% |
TEVA leads this category, winning 1 of 1 comparable metric.
Key Takeaway
TEVA leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VTRS leads in 1 (Valuation Metrics). 1 tied.
Best OverallTeva Pharmaceutical Industr… (TEVA)Leads 4 of 6 categories
Loading custom metrics...
VTRS vs TEVA: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is VTRS or TEVA a better buy right now?
For growth investors, Teva Pharmaceutical Industries Limited (TEVA) is the stronger pick with 4.
3% revenue growth year-over-year, versus -3. 0% for Viatris Inc. (VTRS). Teva Pharmaceutical Industries Limited (TEVA) offers the better valuation at 30. 3x trailing P/E (14. 7x forward), making it the more compelling value choice. Analysts rate Teva Pharmaceutical Industries Limited (TEVA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VTRS or TEVA?
On forward P/E, Viatris Inc.
is actually cheaper at 6. 5x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — VTRS or TEVA?
Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +253.
1%, compared to +31. 5% for Viatris Inc. (VTRS). Over 10 years, the gap is even starker: TEVA returned -24. 0% versus VTRS's -53. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VTRS or TEVA?
By beta (market sensitivity over 5 years), Viatris Inc.
(VTRS) is the lower-risk stock at 0. 99β versus Teva Pharmaceutical Industries Limited's 1. 13β — meaning TEVA is approximately 14% more volatile than VTRS relative to the S&P 500. On balance sheet safety, Viatris Inc. (VTRS) carries a lower debt/equity ratio of 98% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — VTRS or TEVA?
By revenue growth (latest reported year), Teva Pharmaceutical Industries Limited (TEVA) is pulling ahead at 4.
3% versus -3. 0% for Viatris Inc. (VTRS). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to -466. 0% for Viatris Inc.. Over a 3-year CAGR, TEVA leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VTRS or TEVA?
Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.
2% net margin versus -24. 6% for Viatris Inc. — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TEVA leads at 12. 5% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — TEVA leads at 51. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VTRS or TEVA more undervalued right now?
On forward earnings alone, Viatris Inc.
(VTRS) trades at 6. 5x forward P/E versus 14. 7x for Teva Pharmaceutical Industries Limited — 8. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TEVA: 7. 3% to $39. 00.
08Which pays a better dividend — VTRS or TEVA?
In this comparison, VTRS (3.
0% yield) pays a dividend. TEVA does not pay a meaningful dividend and should not be held primarily for income.
09Is VTRS or TEVA better for a retirement portfolio?
For long-horizon retirement investors, Viatris Inc.
(VTRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 99), 3. 0% yield). Both have compounded well over 10 years (VTRS: -53. 8%, TEVA: -24. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VTRS and TEVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: VTRS is a mid-cap income-oriented stock; TEVA is a mid-cap quality compounder stock. VTRS pays a dividend while TEVA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(VTRS: 5.0% · TEVA: 2.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.